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Abstract 
Most of the multidrug resistant human tumor cell lines overexpress the MDRl gene product P-glycoprotein (P-gp) which is believed to function 
as an energy-dependent drug et&ix pump. Here we describe a novel method that allows the kinetic characterization of P-gp-mediated active drug 
transport. This method is based on the fluorescence quenching of anthracyclines transported into DNA-loaded plasma membrane vesicles. The uptake 
of daunorubicin (DNR) into the plasma membrane vesicles was saturable in terms of the extravesicular DNR concentration with a K,,, of 1.5 f 0.1 
PM. This transport occured by a cooperative process with a Hill coefficient close to 2 for DNR. A model is discussed in which P-gp pumps two 
molecules of drug per turnover. 
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1. Introdwtion 
The MDR gene product P-glycoprotein (P-gp) is in- 
volved in the resistance to a wide range of structurally 
and functionally unrelated drugs used in cancer chemo- 
therapy [l]. The resistance mechanism associated with 
P-gp overexpression has been shown to be due to an 
increase of drug efllux rate [2], subsequent to drug et%ux 
against the concentration gradient [3]. Horio et al. [4], 
showed that an ATPase activity was associated with drug 
transport. P-gp is a plasma membrane protein and a 
member of the ATP-binding cassette superfamily [5]. The 
mechanism by which P-gp transports drugs and the basis 
for its limited specificity are not yet clear. 
A kinetic study of the pump activity of P-gp should 
lead to functional information with implications for the 
mechanism of the active transport. However the in situ 
substrate concentration cannot easily be determined. 
Only recently, methods have been developed through 
which kinetic information concerning P-gp could be de- 
rived from results obtained with intact cells [6]. For a 
further characterization of P-gp transport kinetics, ex- 
periments with inside-out plasma membrane vesicles are 
required. 
Towards this aim, we prepared DNA-containing 
plasma membrane vesicles from the human ovarian car- 
cinoma cell line A2780 and its drug-resistant derivative 
*Corresponding author. Fax: (31) (20) 5122029. 
Abbreviations: MDR, multidrug-resistant/resistance; P-gp, P-glycopro- 
tein; DNR, daunorubicin; Dox, doxorubicin; PBS, phosphate-buffered 
saline; PMSF, paramethyl sulfonyl fluoride. 
2780AD which contains a high level of P-gp [6]. Previous 
measurements using plasma membrane preparations 
have shown an accumulation of drug [7]. However, this 
method used radioactive drugs which may present a 
number of limitations. One is the high non-specific bind- 
ing of these hydrophobic drugs to the lipid bilayer, which 
prevents measurements at low drug concentration in- 
cluding concentrations which give half-stimulation of the 
ATPase activity [S]. A second limitation concerns the 
maximal accumulation of drugs, which is reached too 
rapidly to measure accurately initial transport rates. 
Thirdly, the earlier method is noncontinuous with time. 
Furthermore, drug etllux during vesicle filtration may 
compromise the results. We have developed an experi- 
mental model system for P-gp which lacks these three 
limitations. This system was adapted from previous 
work performed with DNA containing large unilamellar 
vesicles [9]. We have used the system to examine the 
P-gp-mediated transport of DNR kinetically. 
2. Materials and methods 
2.1. Chemicals 
Daunorubicin hydrochloride was obtained from Specia (France) and 
doxorubicin hydrochloride from Farmitalia (Italy). ATP, reduced Tri- 
ton X-100, purified calf thymus DNA, PMSF and DNase I were pur- 
chased from Sigma Chemical Company (St. Louis, MO, USA). Culture 
plastics were from Nunc (Roskilde, Denmark). Cell culture media and 
supplements were obtained from Flow Laboratories (Irvine, UK). 
2.2. Cells 
The multidrug-resistant 2780AD human ovarian carcinoma cell line 
and its drug-sensitive A2780 parent cell line were obtained from Dr. 
R.F. 0~01s (National Cancer Institute, Bethesda, MD, USA). Cells 
were maintained in the continuous presence of 2 PM doxorubicin until 
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two weeks before the experiments. Cells were grown at 37°C in a 
humidified atmosphere of 5% CO, in Dulbecco’s modified essential 
medium supplemented with 7.5% heat-inactivated fetal calf serum. The 
cell lines were negative for mycoplasma s checked with the myco- 
plasma T.C. kit @en-Probe Inc., San Diego, CA, USA). 
2.3. DNA containing plasma membrane vesicles 
Crude membrane vesicles were prepared from drug-sensitive A2780 
and MDR 2780AD cell lines as follows. Cells (40. lo7 for A2780 and 
30. lo7 for 2780AD) were harvested, homogenized by potter- 
ing in 100 mM KCI, 5 mM MgCl,, 25 mM Tris-HCl @H 7.4) and 1 mM 
PMSF was present to inhibit protease activity. The homogenate was 
centrifuged at 4,000 rpm for 15 min at 4°C to spin down nuclei and 
mitochondria. The supematant was layered onto a 20%/30%/50% dis- 
continuous sucrose gradient in 10 mM Tris-HCl (pH 7.4), and then 
centrifuged for 7 h at 35,000 rpm, at 4°C using a 70.1 Ti rotor. The 
plasma membrane vesicle fraction at the 30%/50% interface was col- 
lected, diluted in PBS buffer at pH 7.4 and then centrifuged for 1 h at 
35,000 rpm using a 70.1 Ti rotor. The freshly prepared vesicle pellet was 
diluted in 0.33 ml PBS (pH 7.4) containing 10% glycerol and stored at 
-70°C prior to use. The plasma membrane preparation was thawed and 
resuspended in a DNA solution 10 mM previously ultrasonicated at 
maximal power (Soniprep type 150, MSE, Scientific Instruments, 
Loughborough, UK). Prior to resuspension in a DNA solution, the 
plasma membrane protein concentrations were determined by using a 
Biorad assay. This DNA vesicle suspension was sonicated in an ultra- 
sonication bath (Branson type 5200) at 4°C during 5 min. The external 
DNA was hydrolysed in the presence of 100 units/ml of DNase I and 
1.5 mM MgCl, at 37°C for 1.5 h. The reaction was stopped by addition 
of 2 mM EDTA and the suspension was centrifuged at 4,000 rpm, 4” C 
during 10 min. The DNA-containing vesicle pellet was resuspended in 
2 ml and 1.4 ml PBS, pH 7.4, for vesicles from 278pD and A2780 cells, 
respectively. 
2.4. Determination of the amount of DNA encapsulated in plasma 
membrane vesicles 
A total of 0.5 ml PBS (pH 7.4) containing 0.8 pM Dox was put into 
a cuvette in a spectrofluorometer (FluoroMax, SPEX Industries Inc.). 
The temperature was kept at 37°C. Aliquots of DNA were added 
stepwise resulting in a quenching of the fluorescence mission intensity 
of the drug at 590 nm when excited at 490 nm. The slit widths were 1 
mm. A calibration curve was obtained by plotting the fluorescence 
intensity at 590 nm as a function of the DNA concentration in the 
presence of 0.1% reduced Triton X-100. Under the same conditions, an 
aliquot of DNA-vesicle suspension was added to 0.8 PM Dox in the 
presence of 0.1% reduced Triton X-100. 
The addition of 0.1% reduced Triton X-100 by itself did not modify 
the fluorescence mission of the Dox and DNR. DNA appeared to be 
well entrapped in the vesicles because rapid quenching of Dox fluores- 
cence by added vesicles occurred only after addition of reduced Triton 
X-100 which means that DNA was not accessible to the drug present 
in the cuvette. 
2.5. Measurement of the initial rate of uptake of DNR in DNA- 
containing vesicles 
The kinetics of DNR uptake by DNA-containing vesicles was studied 
using a fluorometric approach developed by Frezard and Gamier- 
Suillerot and based on DNR fluorescence quenching upon intercalation 
between the base pairs of DNA [lo]. In such systems the fluorescence 
of anthracvclines is not affected by their interaction with the lipid 
bilayer [l 1 j. All experiments were conducted in a 1 cm quartz cuvdtte 
at 37°C. containing 0.5 ml of PBS plus 1 mM of ATP and 0.9 mM 
MgCl, at pH 7.4 anld different DNR concentrations. The various solu- 
tions of ATP, MgCl, and DNR were preincubated at 37°C for at least 
30 min before adding the vesicles because DNR fluorescence quenched 
somewhat upon addition of ATP. Immediately after adding 6 ~1 of 
DNA-vesicle suspension (containing 1.6 pug or 3 pug protein for 2780AD 
and A2780, respectively), the initial rate of uptake of the drugs was 
measured as the rate at which the fluorescence of DNR decreased. That 
rate was calculated from Eq. (I), 
Y, = (dF/dt), = ,, [drug]/{ F, . [vesicle]} (I) 
where (dF/dt) is the initial rate of change of fluorescence (see Fig. 1); 
vi, the initial rate of drug uptake, F,, the total drug fluorescence at t = 0 
and F the fluorescence of the drug at any time. The uptake was followed 
as a function of time, and the rate of uptake was essentially constant 
for more than 60 s. The initial rate of drug uptake was evaluated from 
the change in fluorescence immediately after adding the vesicles to the 
change 60 s later. Medium background fluorescence was less than 10% 
of the drug fluorescence for each DNR concentration used in the up- 
take measurements. Moreover, we have determined that the change of 
rate of DNR fluorescence observed was due to the quenching of DNR 
fluorescence upon intercalation with DNA present in the vesicles and 
not to the interaction with ATP. We so calculated the rate of change 
of DNR fluorescence in the presence of 1 mM ATP which was less than 
1.5%/min at the lowest DNR concentration used. 
3. Results 
3.1. ATP-dependent ransport of DNR into DNA- 
containing plasma-membrane v sicles 
To examine the kinetic properties of P-glycoprotein, 
we isolated plasma membrane vesicles from the mul- 
tidrug resistant cell line 2780AD. Proper kinetic assess- 
ment of transport is greatly facilitated by maintaining the 
concentration of the transported substance low in the 
compartment into which it is transported (zero trans up- 
take). To achieve this aim, we loaded plasma membrane 
vesicles with sufficient DNA to trap the imported drug. 
Because binding of DNR to DNA quenches the fluores- 
cence of the drug, transport of this drug into vesicles 
containing DNA should be accompanied by a decrease 
of fluorescence. Indeed the fluorescence of DNR prein- 
cubated in the presence of Mg2’ and ATP decreased 
upon addition of plasma membrane vesicles prepared 
from MDR cells (Fig. 1, trace 3). When ATP was absent 
(not shown) or verapamil was present (Fig. 1, trace 2) 
this rate was significantly reduced. The rate obtained 
with vesicles from drug-sensitive cells (Fig. 1, trace 1) 
was even lower. Verapamil is a known inhibitor of P-gp- 
mediated DNR transport [l 11. 
The rate of decrease fluorescence should reflect the 
rate at which the drug is taken up into the vesicles. The 
rate of fluorescence decrease was virtually constant for 
1 min, allowing accurate assessment of the initial rate of 
drug uptake into vesicles. 
3.2. Substrate cooperativity of drug transport 
We examined the kinetics of the ATP-dependent DNR 
uptake. Fig. 2 shows that the uptake rate depended on 
the concentration of DNR both in vesicles from the 
MDR and the drug-sensitive cell line. The difference 
between the two curves should represent he contribution 
of the MDR-related pumping to the uptake. That differ- 
ence was a saturating function of the DNR concentra- 
tion (not shown). A Terre11 Hill plot [12] of the MDR- 
dependent ransport confirmed the saturability and esti- 
mated a K, of 1.5 + 0.1 PM (Fig. 3). In addition, it is 
suggested that the MDR-related transport is cooperative 
in DNR concentration with an index of cooperatively 
slightly higher than 2. 
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Fig. 1. Fluorometric determination of the initial rate of uptake of DNR into DNA-containing plasma membrane vesicles. The fluorescence intensity 
was recorded at a wavelength of 590 mn; the excitation wavelength was 490 nm. To a total of 0.5 ml, 1.45 pM DNR solution and 1 mM MgATP 
was added, and the decrease of DNR fluorescence was recorded as a function of time at 37°C. Trace 1 and trace 3: DNA-loaded vesicles derived 
from drug sensitive A2780 and drug resistant 278wD cells, respectively. Trace 2: vesicles from 27fKP cells in the presence of 25 PM verapamil. 
4. Discussion 
A new method was developed for measurement of the 
kinetics of anthracycline transport mediated by P-gp. 
Although earlier methods allowed the demonstration of 
such transport, they were not suitable for kinetic studies 
owing to the difficulty of assaying truly initial transport 
rates because the intravesicular drug concentration in- 
creased significantly already when the first data points 
were collected. This essential problem has been circum- 
vented in the approach presented here by trapping trans- 
ported anthracyclines into DNA included in the plasma 
membrane vesicles. Moreover, because binding to the 
DNA affects DNR fluorescence, this introduced the pos- 
sibility to assay drug transport through fluorescence 
measurement. Importantly, the new method does not 
DNR medium concentration (PM) 
Fig. 2. Initial uptake of DNR by DNA containing vesicles as a function 
of DNR concentration. The DNA-containing vesicle suspension de- 
rived from the drug-resistant 2780m (upper trace) or the drug-sensitive 
A2780 (lower trace) cell line. 
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Fig. 3. T. Hill plot of the MDR-related transport data. The difference in transport rate between the vesicles form the 278tiD and the A2780 cell line 
is called v and plotted here. For the two transport dam indicated by an arrow, we used the drawn line (-) in order to calculate v from Fig. 2. The 
maximum rate V was estimated by fitting the data to an A.V. Hill equation (not shown). 8 = v/V. The Hill coefficient is given by the slope of the 
curve at 6Qr multiplied by 4. The curve has been obtained by fitting the data with to an A.V. Hill equation with a cooperativity index of 2.2. 
require the filtration of the plasma membrane vesicles 
required in the earlier method, and is therefore insensi- 
tive to etflux during that separation step. As ATP cannot 
cross the plasma membrane to any significant extent, 
only the inverted vesicles can actively accumulate DNR. 
Consequently, the right-side-out subpopulation should 
remain silent in this active drug transport process but 
will contribute to non-specific binding of drugs and to 
passive transport. 
DNA molecules were well encapsulated into the vesi- 
cles: addition of vesicles to a suspension containing 0.8 
PM Dox did not immediately quench the Dox fluores- 
cence. A subsequent addition of 0.1% reduced Triton 
X-100 did lead to quenching of about 50% of the fluores- 
cence (not shown). The encapsulated DNA concentra- 
tion in the assays was about 5 PM base pairs (on the basis 
of the total cuvette volume). These results suggest hat 
our experimental system could be used in initial anthra- 
cycline uptake measurements. 
We measured the initial uptake rate of DNR as a 
function of increasing concentrations of this drug. We 
observed that the dependence of drug pumping on drug 
concentration was not simply hyperbolic, but positively 
cooperative. In order to determine the Hill coefficient, 
we plotted the curve 0 = j(ln[DNR]) where 0 is v/V and 
[DNR] the medium DNR concentration [131. The result- 
ing slope at O,,, multiplied by 4 gives a Hill coefficient 
close to 2, which suggests a cooperative transport of two 
daunorubicin molecules via the P-gp which has also been 
described by Spoelstra et al. [13,14]. 
In the view of this result we propose the existence of 
two binding sites on the P-gp. Only after two drug mole- 
cules have bound, the pump may allow a conformation 
compatible with an active drug transport. After releasing 
both molecules of drug outside the cells, the unloaded 
P-gp may recover its native form. 
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